Phase II study of E7070 in patients with metastatic melanoma

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 158-161

  Smyth, John F ^a   Aamdal, S ^b   Awada, A ^c   Dittrich, C ^d   Caponigro, F ^e   Schoffski P ^f   Gore, M ^g   Lesimple, T ^h   Djurasinovic, N ⁱ   Baron, B ⁱ   Ravic, M ^j   Fumoleau, P ^j   Punt, C J A ^k  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c JULES BORDET INSTITUTE   (Belgium)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h Centre Eugene Marquis   (France)

ⁱ EORTC DATA CENTER   (Belgium)

^j CENTRE RENÉ GAUDUCHEAU   (France)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INDISULAM; SULFONAMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GANGRENE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY REACTION; INFUSION REACTION; INJECTION SITE REACTION; LEUKOPENIA; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOLOGICAL PROCEDURES; SIDE EFFECT; SKIN EXFOLIATION; SKIN METASTASIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

EID: 19944427395     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi016     Document Type: Article

References (8)

1. Coleman MP, Babb P, Damiecki P et al. Cancer survival trends in England and Wales, 1971-1995: Deprivation and NHS region Studies in Medical and Population Subjects (no 61). London: The Stationary Office 1999; 331-342.
2. Ozawa Y, Sugi N, Nagasu T et al. E7070, a novel sulphonamide agent with potent anttumour activity in vitro and in vivo. Eur J Cancer 2002; 37: 2275-2282.
3. Fukuoka K, Usuda J, Iwamoto Y et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 2001; 19: 219-227.
4. Oda Y, Owa T, Sato T et al. Quantitative chemical proteomics for identifying candidate drug targets. Anal Chem 2003; 75: 2159-2165.
5. Raymond E, Ten Bbokkel Huinink WW, Taieb J et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell cycle inhibitor, administered as a one hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 2002; 20: 3508-3521.
6. Punt CJ, Fumoleau P, van de Walle B et al. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol 2001; 12: 1289-1293.
7. Dittrich C, Dumez H, Calvert H et al. Phase I and pharmacokinetic study of E7070 a chloroindolyl-sulphonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 2003; 9: 5195-5204.
8. Terret C, Zanetta S, Roche H et al. Phase I and pharmacokinetic study of E7070 [N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] given as a five day continuous infusion repeated every three weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 2003; 39: 1097-1104.